EA200970396A1 - Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность - Google Patents

Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность

Info

Publication number
EA200970396A1
EA200970396A1 EA200970396A EA200970396A EA200970396A1 EA 200970396 A1 EA200970396 A1 EA 200970396A1 EA 200970396 A EA200970396 A EA 200970396A EA 200970396 A EA200970396 A EA 200970396A EA 200970396 A1 EA200970396 A1 EA 200970396A1
Authority
EA
Eurasian Patent Office
Prior art keywords
improved stability
soft capsules
capsules containing
palonosetron hydrochloride
dosage forms
Prior art date
Application number
EA200970396A
Other languages
English (en)
Other versions
EA016455B1 (ru
Inventor
Даниеле Бонадео
Джорджо Кальдерари
Энрико Бралья
Риккардо Бралья
Original Assignee
Хелсинн Хелткэр С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970396(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Хелсинн Хелткэр С.А. filed Critical Хелсинн Хелткэр С.А.
Publication of EA200970396A1 publication Critical patent/EA200970396A1/ru
Publication of EA016455B1 publication Critical patent/EA016455B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предусматриваются твердые пероральные дозированные формы палоносетрона гидрохлорида, способы применения дозированных форм для лечения рвоты и способы получения дозированных форм. Дозированные формы имеют улучшенную стабильность и биологическую доступность и предпочтительно находятся в форме капсул, наполненных жидкостью.
EA200970396A 2006-10-24 2007-10-19 Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность EA016455B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24
PCT/EP2007/009098 WO2008049552A1 (en) 2006-10-24 2007-10-19 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Publications (2)

Publication Number Publication Date
EA200970396A1 true EA200970396A1 (ru) 2009-10-30
EA016455B1 EA016455B1 (ru) 2012-05-30

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970396A EA016455B1 (ru) 2006-10-24 2007-10-19 Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность

Country Status (36)

Country Link
US (2) US20080152704A1 (ru)
EP (1) EP1940366B9 (ru)
JP (1) JP5144527B2 (ru)
KR (1) KR101441459B1 (ru)
CN (1) CN101573106B (ru)
AR (1) AR063362A1 (ru)
AT (1) ATE427742T1 (ru)
AU (1) AU2007308378B2 (ru)
BR (1) BRPI0718497B1 (ru)
CA (1) CA2666512C (ru)
CL (1) CL2007003055A1 (ru)
CO (1) CO6160289A2 (ru)
CR (1) CR10728A (ru)
CY (1) CY1109914T1 (ru)
DE (1) DE602007000856D1 (ru)
DK (1) DK1940366T3 (ru)
EA (1) EA016455B1 (ru)
ES (1) ES2325339T3 (ru)
GT (1) GT200900096A (ru)
HK (1) HK1117769A1 (ru)
HN (1) HN2009000785A (ru)
HR (1) HRP20090341T1 (ru)
IL (1) IL198225A (ru)
ME (1) ME01949B (ru)
MX (1) MX2009004461A (ru)
NO (1) NO342353B1 (ru)
NZ (1) NZ576237A (ru)
PL (1) PL1940366T3 (ru)
PT (1) PT1940366E (ru)
RS (1) RS50842B (ru)
SI (1) SI1940366T1 (ru)
SV (1) SV2009003238A (ru)
TW (1) TWI367212B (ru)
UA (1) UA97653C2 (ru)
WO (1) WO2008049552A1 (ru)
ZA (1) ZA200902773B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090082A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
WO2010077669A2 (en) 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
US20120253046A1 (en) * 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2361090B1 (en) * 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
CN106974912A (zh) 2011-10-18 2017-07-25 赫尔辛医疗股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
CN107137374B (zh) * 2012-06-02 2020-04-07 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
WO2014147096A1 (en) * 2013-03-19 2014-09-25 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3087987A4 (en) * 2013-12-23 2017-08-02 Samyang Biopharmaceuticals Corporation Pharmaceutical composition containing palonosetron
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) * 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
DE3687080T2 (de) * 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
KR970007917B1 (ko) * 1989-11-28 1997-05-17 신텍스 인크. 신규 삼환식 화합물
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
CA2666512A1 (en) 2008-05-02
ME01949B (me) 2010-08-31
PT1940366E (pt) 2009-06-17
RS50842B (sr) 2010-08-31
EP1940366B1 (en) 2009-04-08
TW200827355A (en) 2008-07-01
AR063362A1 (es) 2009-01-21
AU2007308378B2 (en) 2013-02-21
PL1940366T3 (pl) 2009-09-30
NO342353B1 (no) 2018-05-07
DK1940366T3 (da) 2009-06-29
KR101441459B1 (ko) 2014-09-18
GT200900096A (es) 2011-08-29
CY1109914T1 (el) 2014-09-10
AU2007308378A1 (en) 2008-05-02
TWI367212B (en) 2012-07-01
NZ576237A (en) 2011-12-22
CO6160289A2 (es) 2010-05-20
CL2007003055A1 (es) 2008-03-24
DE602007000856D1 (de) 2009-05-20
BRPI0718497A2 (pt) 2014-07-08
ATE427742T1 (de) 2009-04-15
MX2009004461A (es) 2009-09-16
IL198225A (en) 2013-03-24
ZA200902773B (en) 2010-03-31
CN101573106B (zh) 2013-07-24
UA97653C2 (ru) 2012-03-12
US20080152704A1 (en) 2008-06-26
US20170035748A1 (en) 2017-02-09
SV2009003238A (es) 2009-11-09
HK1117769A1 (en) 2009-01-23
WO2008049552A1 (en) 2008-05-02
ES2325339T3 (es) 2009-09-01
JP2009507933A (ja) 2009-02-26
CA2666512C (en) 2014-05-27
EP1940366B9 (en) 2009-12-02
BRPI0718497B1 (pt) 2024-02-06
HN2009000785A (es) 2011-10-14
HRP20090341T1 (en) 2009-07-31
JP5144527B2 (ja) 2013-02-13
CN101573106A (zh) 2009-11-04
EP1940366A1 (en) 2008-07-09
SI1940366T1 (sl) 2009-08-31
EA016455B1 (ru) 2012-05-30
KR20090073234A (ko) 2009-07-02
NO20091945L (no) 2009-05-25
CR10728A (es) 2009-07-23
IL198225A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
EA200970396A1 (ru) Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность
DE602005026031D1 (de) Kristalline formen von (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
IL208832A (en) 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation
EA201300465A1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EP2526933A3 (en) Inhibitors of bruton's tyrosine kinase
EA201001856A1 (ru) Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона
PH12015501955A1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
NO345140B1 (no) Anvendelse av humane IL-1beta bindende antistoffer og farmasøytiske sammensetninger inneholdende slike, for fremstilling av et medikament for behandling av juvenil reumatoid artritt
DK1720544T3 (da) Nye azabicykliske derivater, fremstillingsmetode hertil og farmaceutiske sammensætninger indeholdende disse
BRPI0923164A2 (pt) formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica.
EP1972251A4 (en) CAPSULE TYPE CONTAINER AND ADMINISTRATION METHOD USING THE SAME
DK1910288T3 (da) 3-aminocarbazolsammensætninger, farmaceutiske sammensætninger, der indeholder disse, samt fremgangsmåde til deres fremstilling
DK2245026T3 (da) Spirocycliske heterocycler, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
EA201691869A1 (ru) Стабильная комбинированная фармацевтическая композиция
EP2366691A4 (en) NITROPYRIDINYL ETHYLENE HYIN, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, SYNTHESIS METHOD AND APPLICATIONS THEREOF
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
EA200701072A1 (ru) Препараты бензотиазола и их применение
DK2067779T3 (da) Tiotropiumsalte, fremgangsmåde til deres fremstilling og lægemiddelformuleringer indeholdende disse
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
CY1118132T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ (1R,4R)-6'-ΦΘΟΡΟ-Ν,Ν-ΔΙΜΕΘΥΛ-4-ΦΑΙΝΥΛ-4',9'-ΔΙΥΔΡΟ-3´H-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ